Nachrichten zur Angiodynamics Inc. Aktie

Angiodynamics (ANGO) CEO Clemmer buys $111,500 in shares…

Even 37 years after its founding, AngioDynamics still cant earn a profit.…

…

Earnings call transcript: AngioDynamics beats Q1 FY2026 forecasts, shares surge…

AngioDynamics (ANGO) konzentriert sich als Medizintechnikunternehmen auf minimalinvasive Behandlungslösungen von Krebs und peripheren Gefäßerkrankungen. Das wachstumsstarke MedTech-Segment erhöht das... …

AngioDynamics earnings beat by $0.02, revenue topped estimates…

AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss…

AngioDynamics big Q4 earnings beat wasnt as impressive as it first seemed.…

…

Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Lets find out.…

AngioDynamics (ANGO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.…

AngioDynamics (ANGO) durchläuft einen Transformationsprozess und will sich auf wachstumsstarke Medizintechnikmärkte wie Prostatakrebs oder Thrombektomie konzentrieren. Das adressierbare Marktpotenzial... …

Strategischer Fokus auf die Erweiterung des MedTech-Angebots führt zu einem beeindruckenden Umsatzwachstum von 22,2 % in diesem Segment. Kreditlinie…

…

AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the…

AngioDynamics (ANGO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

AngioDynamics (ANGO) befindet sich laut CEO Jim Clemmer in diesem Jahr an einem wichtigen Wendepunkt für die Unternehmensentwicklung. In…

…

…

AngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the…

AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

AngioDynamics latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient…

The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after…

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

AngioDynamics announces the receipt of CPT Category I code for IRE technology.…

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med…

…

…

AngioDynamics RECOVER-AV trial evaluates the AlphaVac F1885 Systems safety and efficacy in treating acute pulmonary embolism in Europe.…

The mean of analysts price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly…

…

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the…

Earnings call: AngioDynamics sees steady growth in FY 2024 results…

…

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range…

…

Earnings call: AngioDynamics posts mixed Q3 results, focuses on growth…

AngioDynamics (ANGO) announces the FDAs approval of its AlphaVac F1885 System, which is likely to expand the range of therapy…

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.…

…

AngioDynamics (ANGO) announces its settlement agreement with BDs affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.…